加载中
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
常规交易时段
US$40.00
−US$0.84 · -2.06%
盘中时间采用ET。市场数据可能有所延迟。
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
日内区间
当前US$40.00
52周区间
当前US$40.00
盘中时间采用ET。市场数据可能有所延迟。
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
日内区间
当前US$40.00
52周区间
当前US$40.00
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 26.3万 USD | — | — | — | — |
| 毛利 | −26.3万 USD | — | — | — | — |
| 研究与开发 | 8585.6万 USD | 8077.8万 USD | 6457.4万 USD | 3102.2万 USD | 2047.4万 USD |
| 销售、一般及管理费用 | 3380.2万 USD | 2377.6万 USD | 1895.5万 USD | 776.9万 USD | 428.8万 USD |
| 营业费用 | 1.19亿 USD | 1.05亿 USD | 8352.9万 USD | 3879.1万 USD | 2476.2万 USD |
| 利息收入 | 1601.3万 USD | 1489.1万 USD | 1196.7万 USD | 112.9万 USD | 2.2万 USD |
| 折旧和摊销 | 26.3万 USD | 31.7万 USD | 29.7万 USD | 21.5万 USD | 11.5万 USD |
| 营业利润 | −1.2亿 USD | −1.05亿 USD | −8352.9万 USD | −3879.1万 USD | −2476.2万 USD |
| 净利润 | −1.04亿 USD | −8902.4万 USD | −7158.4万 USD | −3766.2万 USD | −2474万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$75.14
上涨空间 87.85%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2023年2月24日 | 1:4 | — | — |
已生效 2023年2月24日
1:4
报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM6100.17万0.08%787.4亿 USD0.19%US$276.43-0.53%
iShares Russell 2000 Growth ETFIWO2195.71万0.16%139.17亿 USD0.24%US$351.36-0.67%
iShares Biotechnology ETFIBB1930.7万0.18%108.2亿 USD0.44%US$201.06-1.57%
Dimensional - US Small Cap ETFDFAS1447万0.04%338.04亿 USD0.31%US$78.03-0.18%
Vanguard Russell 2000 ETFVTWO1425.52万0.08%180亿 USD0.06%US$111.63-0.57%
Schwab U.S. Small-Cap ETFSCHA1371.52万0.06%217.13亿 USD0.03%US$32.505-0.47%
iShares U.S. Pharmaceuticals ETFIHE903.25万0.58%15.52亿 USD0.37%US$97.54-2.64%
Vanguard Health Care ETFVHT852万0.04%220亿 USD0.09%US$316.51-1.30%iShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares U.S. Pharmaceuticals ETFIHEVanguard Health Care ETFVHTAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
